Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 54% Improvement Relative Risk Ventilation 65% HCQ for COVID-19  Heberto et al.  LATE TREATMENT Is late treatment with HCQ + AZ beneficial for COVID-19? Prospective study of 254 patients in Mexico Lower mortality (p=0.04) and ventilation (p=0.008) with HCQ + AZ c19hcq.org Heberto et al., IJC Heart & Vasculature, Sep 2020 Favors HCQ Favors control

Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)

Heberto et al., IJC Heart & Vasculature, doi:10.1016/j.ijcha.2020.100638
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Observational prospective 254 hospitalized patients, HCQ+AZ mortality odds ratio OR 0.36, p = 0.04. Ventilation OR 0.20, p = 0.008.
risk of death, 53.9% lower, RR 0.46, p = 0.04, treatment 139, control 115, odds ratio converted to relative risk.
risk of mechanical ventilation, 65.1% lower, RR 0.35, p = 0.008, treatment 139, control 115, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Heberto et al., 12 Sep 2020, prospective, Mexico, peer-reviewed, 8 authors, this trial uses multiple treatments in the treatment arm (combined with AZ) - results of individual treatments may vary. Contact: vic_plata@hotmail.com, juancarlosplatacorona3@gmail.com.
This PaperHCQAll
Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19)
Aquino Bruno Heberto, Plata Corona Juan Carlos, Castro Rubio José Antonio, Pulido Pérez Patricia, Torres Rasgado Enrique, Morales Portano Julieta Danira, Gómez Álvarez Enrique Benito, Merino Rajme José Alfredo
IJC Heart & Vasculature, doi:10.1016/j.ijcha.2020.100638
Background: Respiratory illnesses is the most common manifestation of Coronavirus disease 2019 (COVID-19); however, myocardial injury has recently emerged as a frequent complication. Methods: An observational, longitudinal, prospective, and multicenter study of hospitalized Mexican patients was made. We assessed the prevalence of myocardial injury and its relationship with complications and mortality. Results: 254 COVID-19 patients were included. Their average age was 53.8 years old, 167 (65.7%) were male and 87 (34.3%) female. According to troponin levels, two populations were generated, those with and without myocardial injury. There was no difference in gender or age between both groups. However, there was a greater proportion of obesity and hypertension in myocardial injury group. Multivariate logistic regression analysis revealed that obesity (OR 2.029, 95% CI 1.039-3.961; p = 0.038), arterial oxygen saturation <90% (OR 2.250, 95% CI 1.216-3.560; p = 0.025), and systolic blood pressure <90 mmHg (OR 2.636, 95% CI 1.530-4.343; p = 0.042), were directly related to higher levels of troponins. Multivariate cox proportional hazards analysis showed that primary endpoint (mortality) was determined by overweight/obesity (OR 1.290, 95% CI 0.115-0.730; p = 0.009), ferritin levels (OR 1.001, 95% CI 1.000-1.001; p < 0.001), myocardial injury (OR 3.764, 95% CI 1.307-10.838; p = 0.014), septic shock (OR 4.104,; p = 0.024), acute respiratory distress syndrome (OR 3.001, 95% CI 1.008-10.165; p = 0.040), and treatment with Hydroxychloroquine/Azithromycin (OR 0.357, 95% IC 0.133-0.955; p = 0.040). Secondary endpoint (Mechanical ventilation risk) was associated to the same factors. Conclusions: Myocardial injury represents an increased risk of complications and death in Mexican hospitalized patients with COVID-19.
CRediT authorship contribution statement Aquino Bruno Heberto: Conceptualization, Methodology, Validation, Investigation, Formal analysis, Writing -original draft, Writing -review & editing, Visualization, Supervision, Project Declaration of Competing Interest The authors report no relationships that could be construed as a conflict of interest. Author's contributions and consent for publication As the corresponding author, I declare that all authors in this paper contribute substantially in the work design, analysis, data interpretation, drafting, and intellectual content. Finally all authors approved this version to be published. Author's agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Manuscript We declare this manuscript has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities -tacitly or explicitly -at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation. Ethics approval This research was approved by bioethics committee of hospitals involved. We certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later..
References
Arentz, Yim, Klaff, Lokhandwala, Riedo et al., Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State, JAMA
Bajema, Oster, Mcgovern, Lindstrom, Stenger et al., Persons evaluated for 2019 novel coronavirus -United States, MMWR Morb. Mortal. Wkly Rep
Barnes, Burnett, Allen, Blumenstein, Clark et al., Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum, J. Thromb. Thrombolysis
Bulut, Kato, Epidemiology of COVID-19, Turk. J. Med. Sci
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int. J. Antimicrob. Agents
Cosyns, Lochy, Luchian, Gimelli, Pontone et al., The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients, Eur. Heart J. Cardiovasc. Imaging
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends
Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol
Han, Xie, Liu, Yang, Liu et al., Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China, J. Med. Virol
Harapan, Itoh, Yufika, Winardi, Keam et al., Coronavirus disease 2019 (COVID-19): A literature review, J. Infect. Public Health
Holshue, Debolt, Lindquist, Lofy, Wiesman et al., First case of 2019 novel coronavirus in the United States, N. Engl. J. Med
Ji, Zhang, Xu, Chen, Yang et al., Prediction for progression risk in patients with COVID-19 Pneumonia: the CALL Score, Clin. Infect. Dis
Kollias, Kyriakoulis, Destounis, Stergiou, Syrigos, Cardiac injury and prognosis in COVID-19: Methodological considerations and updated meta-analysis, J. Infect
Li, Cheng, Fu, Chan, Lee et al., Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study, Circulation
Li, Yang, Zhao, Zhi, Wang et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin. Res. Cardiol
Lippi, Ferrari, Gandini, Gelati, Lo Cascio et al., Analytical evaluation of the new Beckman Coulter Access high sensitivity cardiac troponin I immunoassay, Clin. Chem. Lab. Med
Lippi, Plebani, Laboratory abnormalities in patients with COVID-2019 infection, Clin. Chem. Lab. Med
Lippi, Wong, Henry, Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis, Pol. Arch. Intern. Med
Mccullough, Goyal, Krishnan, Choi, Safford et al., Electrocardiographic findings in coronavirus disease-19: insights on mortality and underlying myocardial processes, J. Card. Fail
Peng, Meng, Guan, Leng, Zhu et al., Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV, Zhonghua Xin Xue Guan Bing Za Zhi
Porcheddu, Serra, Kelvin, Kelvin, Rubino, Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China, J. Infect. Dev. Ctries
Pretorius, Tate, Wilgen, Cullen, Ungerer, A critical evaluation of the Beckman Coulter Access hsTnI: Analytical performance, reference interval and concordance, Clin. Biochem
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Shi, Qin, Shen, Cai, Liu et al., Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China, JAMA Cardiol
Singh, Majumdar, Singh, Misra, Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective, Diabetes Metab. Syndr
Tang, Bai, Chen, Gong, Li et al., Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemost
Thygesen, Alpert, Jaffe, Chaitman, Bax et al., Fourth universal definition of myocardial infarction (2018), J. Am. Coll. Cardiol
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan
Xiong, Redwood, Prendergast, Chen, Coronaviruses and the cardiovascular system: acute and long-term implications, Eur. Heart J
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study, Lancet Respir. Med
Yin, Huang, Li, Tang, Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2, J. Thromb. Thrombolysis
Zhou, She, Wang, Ma, The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease, J. Infect
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhu, Zhang, Wang, Li, Yang et al., A novel coronavirus from patients with Pneumonia in China, 2019, N. Engl. J. Med
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit